Instil Bio, Inc. Reports Q2 2026 Results

What Happened
Instil Bio, Inc. announced a corporate update and reported its financial results for the quarter ended June 30, 2026 via a press release filed as Exhibit 99.1 with a Form 8-K dated August 13, 2026. The filing was signed by Sandeep Laumas, M.D., the company’s Chief Financial Officer and Chief Business Officer.

Key Details

• Filing date: August 13, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: quarter ended June 30, 2026 (Q2 2026).
• Disclosure format: press release attached as Exhibit 99.1; cover page formatted in Inline XBRL (Exhibit 104).
• Form 8-K signed by Sandeep Laumas, M.D. (CFO and CBO).

Why It Matters
This 8-K notifies investors that Instil Bio has released its quarterly results and a corporate update; the press release (Exhibit 99.1) contains the detailed financial metrics—such as revenue, expenses, cash position, and operational highlights—that investors use to evaluate the company’s near-term performance. Retail investors should review the attached press release and subsequent filings (e.g., the company’s 10-Q) for the full financial figures and context.